Europe’s rare cancer community calls for a more radical approach

Anna Wagstaff

The genomic era offers enormous potential for patients with rare cancers, but progress is being held back by structures that separate research from care, regulatory practices that penalise small patient populations, and rules that restrict close working between researchers, companies, patients and regulators.

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.